dc.contributor.author | Esin, Ece | |
dc.contributor.author | Yildiz, Ferah | |
dc.contributor.author | Lacin, Sahin | |
dc.contributor.author | Karakas, Yusuf | |
dc.contributor.author | Gültekin, Melis | |
dc.contributor.author | Dizdar, Ömer | |
dc.contributor.author | Yalçin, Şuayib | |
dc.date.accessioned | 2019-12-10T11:30:51Z | |
dc.date.available | 2019-12-10T11:30:51Z | |
dc.date.issued | 2018 | |
dc.identifier.issn | 1300-4948 | |
dc.identifier.uri | https://doi.org/10.5152/tjg.2018.17660 | |
dc.identifier.uri | http://hdl.handle.net/11655/15819 | |
dc.description.abstract | Background/Aims: An organ preservation approach using chemoradiotherapy has been established for anal cancer. This retrospective cohort study aimed to define the clinico-demographic characteristics and outcomes of cases of human immunodeficiency virus (HIV)-negative anal carcinoma during a period of 20 years in a single comprehensive cancer institute. Materials and Methods: This was a single-center retrospective cohort study of patients who were treated between January 1995 and January 2015. The primary outcome measures that were investigated included overall survival (OS), progression-free survival (PFS), colostomy rates, and colostomy-free survival (CFS). Results: A total of 28 patients who were principally treated with standard 5-fluorouracil + mitomycin combination chemoradiotherapy were eligible for analysis. The 3- and 5-year PFS rates were 92.4% and 63%, respectively. The lower T stage was found to be associated with a prolonged PFS (p=0.001). The 3- and 5-year CFS rates were 84.3% and 74.9%, respectively. A longer CFS was observed with lower T stages (p=0.05). At the last follow-up, 75% of the patients with anal cancer were alive, and 71.4% of the patients were disease free. The median OS was not reached with a median follow-up of 54 months (range, 6-115 months). The 3- and 5-year OS rates were 82% and 71.1%, respectively. No late toxicity was observed during the follow-up period. Discussion: The short- and long-term prognoses of HIV-negative patients with anal squamous cell carcinoma were good, and low-grade toxicity was rare, thereby demonstrating that these patients can be successfully treated in a real-life setting with favorable outcomes. | |
dc.language.iso | en | |
dc.publisher | Aves | |
dc.relation.isversionof | 10.5152/tjg.2018.17660 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Gastroenterology & Hepatology | |
dc.title | Real World Survival Data of A Rare Malignancy: Anal Cancer Results in Hiv Negative Patients From Turkey | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Turkish Journal Of Gastroenterology | |
dc.contributor.department | Radyasyon Onkolojisi | |
dc.identifier.volume | 29 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 411 | |
dc.identifier.endpage | 418 | |
dc.description.index | WoS | |